Overview

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Status:
Recruiting

Trial end date:
2023-11-30

Target enrollment:

Participant gender:

Summary

This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan Cancer Hospital and Research Institute

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel